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INTRODUCTION:  Pancreatic  neuroendocrine  tumors  (PNET)  have an incidence  of one per 100,000  individ-
uals  per  year.  They  represent  about  1–2% of  all  pancreatic  tumors.  PNETs  are  a heterogeneous  group  with
various  clinical  presentations  and  lineage.  Non  functional  PNET  (NF-PNET)  are  incidentally  discovered
in  most  cases.  This  article  presents  a review  of  NF-PNET  and  the  case  of  a patient with  this  disease,  in
addition  to its diagnosis,  clinical  presentation,  and  treatment.
PRESENTATION OF  CASE:  The  patient  is  a 37-year-old  asymptomatic  man  who  was  sent  from  his  reference
unit  because  of  a pancreatic  tumor  that was  visualized  incidentally  during  a laparotomy  performed  three
months  before  due  to an  acute  abdomen  secondary  to blunt  abdominal  trauma.  A  CT scan  was  requested
that  showed  a retroperitoneal  mass  7.5 cm  × 6.6 cm  × 7 cm with  inﬁltration  of the  duodenal  wall.
Endoscopy  was  performed,  which  reported  a duodenal  ulcer  with  nonconclusive  histological  ﬁndings.  A
percutaneous  biopsy  was  obtained  out  and  a diagnosis  of  a neuroendocrine  tumor  was  made.  Chemother-
apy  was  started because  inﬁltration  of the  portomesenteric  axis  was  suspected.  The  patient  presented
signs  of toxicity  during  his  third  cycle  and therefore  was scheduled  for exploratory  laparotomy.  Pancre-
atoduodenectomy  was  performed  with  a histologic  diagnosis  of  a pancreatic  neuroendocrine  tumor.
DISCUSSION: The  presentation  of  a NF-PNET  is nonspeciﬁc.  They  continue  to be  tumors  with  a low  inci-
dence  and  few  studies  directed  toward  early  detection  and  management  have  been  carried  out.  Currently,
CT  scans  are  the  studies  most  used  for  detection.
CONCLUSION: Surgical  treatment  is preferred  in  patients  without  evidence  of unresectability  with  longer
survival.  The  characteristics  of  NF-PNETs  make  their  detection  difﬁcult  and  new  strategies  are  needed
for  early  detection  and  management.  New  studies  in early  stages  with  new  cytotoxics  or  analogs  are
promising.
gical © 2012 Sur
. Introduction
Neuroendocrine tumors comprise a rare group of neoplasms
hat arise from the neuroendocrine system of the intestine. They
ave an incidence of 1 in 100,0001 and it is estimated that at
east 3% of primary neoplasms are derived from the pancreas and
ore than 10% are associated with genetic syndromes such as
EN1.2 By deﬁnition all PNET express neuroendocrine markers
uch as synaptophysin, neuron-speciﬁc enolase and chromogranin
 (present in 88–100% of patients with PNET). At least 14 different
ypes of cells have been implicated to date in their pathogenesis.
his heterogeneity describes the multiple syndromes of overpro-
uction and hypersecretion of hormones, thus PNET are classiﬁed
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as functional or nonfunctional based on the presence or absence,
respectively, of a particular clinical syndrome associated with hor-
mone hypersecretion.3,4 Recent series have stated that NF-PNET
occupy 20–60% of all neuroendocrine tumors.5 NF-PNET are often
found by chance and patients usually present with advanced dis-
ease (>60% have liver metastases). Symptoms can be caused by
tumor growth. Among these is abdominal pain (40–60%), weight
loss (25–50%) and jaundice (30–40%). In recent years there has been
an increase in the incidental diagnosis of NF-PNET with imaging
studies because of their nonspeciﬁc symptoms (over 35% of patients
in some series). Screening asymptomatic individuals result in lower
rates of metastasis, increased resectability, and improved survival.6
We  present a rare case in which a NF-PNET was  found inciden-
tally in a patient with a history of exploratory laparotomy for blunt
abdominal trauma.
Open access under CC BY-NC-ND license. 2.  Case report
The  patient is a 37-year-old man  ﬁrst seen in the unit in
October 2011 because of a tumor of probable pancreatic origin that
NC-ND license. 
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dFig. 1. CT scan showing retroperitoneal lesion at the leve
as found incidentally after exploratory laparotomy for an acute
bdomen secondary to blunt abdominal trauma in October 2010.
rior to the event and even afterwards he never complained of
ain or the presence of an abdominal mass or any other associated
ymptoms, which is why he was referred to our unit for further
anagement.
On admission, an abdominal CT scan was requested, which
howed a retroperitoneal neoplastic lesion in the right upper
uadrant with densities of 30–50 Hounsﬁeld units and a size of
.5 cm × 6.6 cm × 7 cm with enhancement after administration of
ontrast media and inﬁltration of the duodenal wall with compres-
ion of the large vessels (Fig. 1). An endoscopy was  requested and
he ﬁnding of an inﬁltrating duodenal ulcer of probable pancreatic
rigin was reported. A biopsy was performed with a histopatho-
ogical report of mild chronic inﬂammation and edema. It was also
eported that chromogranin, Ca 19-9, CK 7 and 20 were nega-
ive.
With the endoscopy result a percutaneous biopsy was carried
ut, which was reported as a neuroendocrine tumor with intense
ositivity with immunohistochemistry. Neoadjuvant chemother-
py was started on suspicion of inﬁltration of the portomesenteric
xis with dacarbazine, epirubicin, and 5FU, only for 3 cycles
ince the patient had toxicity during the last cycle conducted in
ig. 2. Surgical images that show the neuroendocrine lesion that involves the head of the
uodenum; (a) arrow indicating the portal vein; (b) arrow showing the lesion.e pancreas with duodenal and large vessel compression.
July  2011. He was  then subjected to programmed exploratory
laparotomy where a pancreatoduodenectomy (Whipple proce-
dure) was performed (Fig. 2) with ﬁndings of a tumor of the head
of the pancreas about 7 cm × 4 cm × 7 cm in diameter, well deﬁned,
free in relation to large vessels, indurated, and involving the
duodenum on its posterior and medial wall (Fig. 3). The deﬁnite
histopathological report was that of a neuroendocrine tumor of
the head of the pancreas, with a mitotic index of 1 mitosis per 10
HPF, and lesion-free borders (Fig. 4). The patient had an uneventful
clinical course without complications and is currently in clinical
control and follow-up with improvement.
3. Discussion
NF-PNETs are still considered rare entities, with 10 cases per
million inhabitants. Most are functional tumors and only 15–30%
are NF-PNET.7 They are a heterogeneous group of neoplasms that
are characterized by nonspeciﬁc symptoms, leading to a delay of
several years in their diagnosis; most present liver metastases.8Most of the cases reported in the literature have been as a palpa-
ble abdominal mass with duodenal and gall bladder compression.
Imaging techniques such as computed tomography, ultrasound,
and endoscopic or intraoperative ultrasound have been useful for
 pancreas with inﬁltration and compression of the second and third portion of the
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Fig. 3. Fixed macroscopic specimen of pancreatic neuroendocrine tumor: (a) sagit
iliary canal are seen.
ocating most PNETs greater than 2 cm in diameter, but imaging
echniques have difﬁculty visualizing PNETs less than 5 mm,9 with
ndoscopic ultrasound having the highest sensitivity and speci-
city, 82% and 95%, respectively. Endoscopic ultrasound helps us
o identify tumors in the duodenal wall and peripancreatic nod-
les with a sensitivity of 58%, similar to that of scintigraphy.10
odney et al. reported a sensitivity of 78% in the localization of
esions with computed tomography. Histopathologically, NF-PNET
annot be distinguished from functional tumors by immunohis-
ochemistry. In general, positive staining with chromogranin A
nd synaptophysin conﬁrms the diagnosis and these are elevated
ig. 4. Positive immunohistochemistry reaction: (a) chromogranin positive; (b) synaptopw; (b) posterior view where portions of the duodenum, the gall bladder and the
in  60–100% of NF-PNETs, although it is important to point out
that a negative chromogranin result does not completely rule
out an endocrine tumor since those that usually originate in
the colon and the appendix are chromogranin subtype A nega-
tive, but chromogranin subtype B positive. Somatostatin receptor
scintigraphy, based on the presence of somatostatin receptors
present in 80–90% of all PNETs, is a tool for patients with this
disease.11–13
Initial management of a PNET includes surgical resection
of the tumor. Haynes et al. in a case series of more than 139
patients concluded that those with incidental NF-TNPs should
hysin positive. Both are diagnostic of pancreatic neuroendocrine tumors (400×).
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ndergo tumor resection and careful postoperative surveillance
ven if pathological ﬁndings are suggestive of benign disease.14
 considerable amount of patients with NF-PNETs are diagnosed
ncidentally. In 2010, in a PNET database, the Lee Mofﬁtt Cancer
enter concluded that 26% of tumors were discovered incidentally
nd 55% were in stage I according to AJCC stratiﬁcation. Moreover,
edian patient survival was 103 months in those who already had
ymptoms versus 84 in those who did not.15
Medical treatment with drugs such as somatostatin analogs
re used in patients who do not beneﬁt with surgery alone16,17
nd a chemotherapy regimen with doxorubicin, 5-FU and strepto-
ocin has signiﬁcant activity in patients with locally advanced and
etastatic pancreatic endocrine carcinomas.18 In 2011 two ther-
pies, sunitinib, and everolimus, were approved by the FDA for
se in the control of unresectable PNET. Although everolimus has
o beneﬁts on survival, it does if disease progression is present,
s well as being effective in patients who have been treated
ith somatostatin analogs and/or cytotoxic therapy.19 In February
012, Raymond et al. in a randomized, double-blind, multinational
tudy concluded that daily administration of 37.5 mg  of sunitinib
mproved progression-free survival, overall survival, and the objec-
ive response rate in comparison with a placebo group in patients
ith advanced PNET.20 New cytotoxic therapies such as temozolo-
ide and capecitabine are in phase II studies, but these have not
hown greater effectiveness than the use of streptozocin.
Further studies are still in process, and this latest evidence
hows the need for new management guidelines for patients with
hese characteristics that should be used to make good decisions.
he characteristics of this pathology and its presentation remind
s to continue the search for new strategies for early diagnosis and
reatment.
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